Compare FBRT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBRT | ANL |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.6M | 731.6M |
| IPO Year | N/A | 2022 |
| Metric | FBRT | ANL |
|---|---|---|
| Price | $8.43 | $10.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $11.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 791.5K | 109.1K |
| Earning Date | 04-29-2026 | 04-10-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | $36.02 |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $0.88 |
| 52 Week High | $11.84 | $17.25 |
| Indicator | FBRT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 42.01 |
| Support Level | $8.35 | $9.46 |
| Resistance Level | $9.26 | $12.59 |
| Average True Range (ATR) | 0.22 | 1.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 54.95 | 18.21 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.